Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06948825 · ClinicalTrials.gov registry record · Phase 2

Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes

A Phase 2 study of Weight Loss and Gestational Diabetes Mellitus in Pregnancy, sponsored by George Washington University.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT06948825: Recruiting Phase 2 study of Weight Loss and Gestational Diabetes Mellitus in Pregnancy, sponsored by George Washington University.

NCT06948825 is a Phase 2 study of Weight Loss and Gestational Diabetes Mellitus in Pregnancy that is actively recruiting participants, run by George Washington University. The registered enrollment target is 60 participants, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06948825, a Phase 2 study of Weight Loss and Gestational Diabetes Mellitus in Pregnancy, is actively recruiting participants, sponsored by George Washington University.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to evaluate the effectiveness of a 6-month lifestyle intervention compared to Metformin in postpartum women who have delivered a singleton, live born infant within the last 12 weeks to 1 year and had a pregnancy complicated by gestational diabetes. The main question this study aims to answer is: Is a Lifestyle Intervention or Metformin more effective for weight loss in postpartum women with recent gestational diabetes? Researchers will compare a 6-month Lifestyle Intervention and Metformin to see if either intervention is more effective in achieving weight loss and improving health outcomes. Participants will: * Attend an in-person baseline visit to receive a Bluetooth-enabled scale and Fitbit, have blood drawn for testing, and have their height, weight, and blood pressure measured. Participants will also be asked to bring in their infant, and the study team will measure the infant's weight and length. * Track diet, physical activity, and weight using the Fitbit and Looseit! apps. * Attend weekly online group sessions for the first 4 weeks, then biweekly sessions. * If not meeting weight loss goals, be randomized to either Enhanced Lifestyle Intervention or Metformin arms of the study. * If randomized to Metformin, participants will attend one in-person meeting with the study provider, get blood drawn for testing, and undergo a urine pregnancy test before starting the medication. * Continue with biweekly group sessions or have regular check-in calls. * If randomized to the Enhanced Lifestyle Intervention, participants will get a free Instacart membership, a 1:1 session with the study health counselor focused on meal planning and free grocery delivery once a week for the remainder of the study. * Participants will meet every other week via Zoom with the health counselor and other participants in the enhanced lifestyle arm. * At the end of the 6 months, all participants will come for an in-person visit to get blood drawn for test

Primary Outcome

Weight in kg.

Interventions

  • BEHAVIORAL Lifestyle Intervention
  • DRUG Metformin Hcl 850Mg Tab
  • BEHAVIORAL Enhanced Lifestyle Intervention

Study Locations (1)

District of Columbia

  • Milken Institute School of Public Health - The George Washington University - Washington D.C.

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-27
Est. Completion 2026-11
Phase Phase 2
George Washington University

133 total trials

What NCT06948825 shows while recruiting

NCT06948825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,501-participant average among 116 other Weight Loss trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Weight Loss appearing as the primary indexed condition, and to 3 interventions - of which Lifestyle Intervention is the first listed.

NCT06948825 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06948825 about?

NCT06948825 is a clinical study titled "Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes". The goal of this clinical trial is to evaluate the effectiveness of a 6-month lifestyle intervention compared to Metformin in postpartum women who have delivered a singleton, live born infant within the last 12 weeks to 1 year and had a pregnancy complicated by gestational diabetes. The main questio...

What is the current status of trial NCT06948825?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-10-27. Estimated completion is 2026-11.

What conditions does trial NCT06948825 study?

This clinical trial studies the following conditions: Weight Loss, Gestational Diabetes Mellitus in Pregnancy, Postpartum Care.

What interventions are being tested in trial NCT06948825?

The interventions under investigation include: Lifestyle Intervention (BEHAVIORAL), Metformin Hcl 850Mg Tab (DRUG), Enhanced Lifestyle Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT06948825?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06948825 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Weight Loss

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06948825's enrollment target sits among peer trials

60 67th of 116 higher than 42 of 116 other Weight Loss trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06948825, the US trial registry maintained by the National Library of Medicine. NCT06948825 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.